Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
10
2018
accepted:
08
02
2019
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
26
11
2019
Statut:
epublish
Résumé
Amoebic colitis is the most frequent clinical manifestation of invasive intestinal infection due to Entamoeba histolytica and a common cause of diarrhoea worldwide. Since higher transmission rates are usually related to poor health and exposure to unhygienic conditions, cases reported in Europe usually involve immigrants and international travellers. The goal of this study was to characterise both the clinical and the epidemiological features of a European population diagnosed with amoebic colitis and then to evaluate the diagnostic tools and therapeutic options applied. This was a retrospective observational study in which data from all patients diagnosed with amoebic colitis attending at the International Health Units of two tertiary referral hospitals, Germans Trias i Pujol University Hospital (Badalona, North Barcelona Metropolitan Area) and Vall d'Hebron University Hospital (Barcelona city) between 2007 and 2017 were analysed. During the study period 50 patients were diagnosed with amoebic colitis. Thirty-six (72%) were men, and immigrants accounted for 46% of all cases. Antecedents of any international travel were reported for 28 (56%), the most frequent destinations having been the Indian subcontinent, South and Central America and sub-Saharan Africa. Preexisting pathological conditions or any kind of immunosuppression were identified in 29 (58%) patients; of these, 13 (26%) had HIV infection-all of them men who have sex with men-and 5 (10%) had inflammatory bowel disease. Diarrhoea, abdominal pain and dysentery were the most frequently recorded symptoms of invasive amoebae. Diagnosis was made through microbiological study in 45 (90%) and/or histological identification of amoebae in colon biopsies in 10 (20%). After treatment with metronidazole (82%) or tinidazole (8%), all patients had good outcomes. Post-acute intraluminal treatment was indicated in 28 (56%). Amoebic colitis should be suspected in patients with diarrhoea and compatible epidemiological risk factors (immigration, travelling abroad or men who have sex with men), especially if some degree of immunosuppression concurs. These risk factors must be taken into account in any diagnostic approach to inflammatory bowel disease (IBD), and active searches for stool parasites should be performed in such cases to rule out misdiagnosis or simultaneous amoebic infection. Treatment should include intraluminal anti-amoebic treatment in order to avoid relapse and prevent further spread of the disease.
Sections du résumé
BACKGROUND
Amoebic colitis is the most frequent clinical manifestation of invasive intestinal infection due to Entamoeba histolytica and a common cause of diarrhoea worldwide. Since higher transmission rates are usually related to poor health and exposure to unhygienic conditions, cases reported in Europe usually involve immigrants and international travellers. The goal of this study was to characterise both the clinical and the epidemiological features of a European population diagnosed with amoebic colitis and then to evaluate the diagnostic tools and therapeutic options applied.
METHODS AND RESULTS
This was a retrospective observational study in which data from all patients diagnosed with amoebic colitis attending at the International Health Units of two tertiary referral hospitals, Germans Trias i Pujol University Hospital (Badalona, North Barcelona Metropolitan Area) and Vall d'Hebron University Hospital (Barcelona city) between 2007 and 2017 were analysed. During the study period 50 patients were diagnosed with amoebic colitis. Thirty-six (72%) were men, and immigrants accounted for 46% of all cases. Antecedents of any international travel were reported for 28 (56%), the most frequent destinations having been the Indian subcontinent, South and Central America and sub-Saharan Africa. Preexisting pathological conditions or any kind of immunosuppression were identified in 29 (58%) patients; of these, 13 (26%) had HIV infection-all of them men who have sex with men-and 5 (10%) had inflammatory bowel disease. Diarrhoea, abdominal pain and dysentery were the most frequently recorded symptoms of invasive amoebae. Diagnosis was made through microbiological study in 45 (90%) and/or histological identification of amoebae in colon biopsies in 10 (20%). After treatment with metronidazole (82%) or tinidazole (8%), all patients had good outcomes. Post-acute intraluminal treatment was indicated in 28 (56%).
CONCLUSIONS
Amoebic colitis should be suspected in patients with diarrhoea and compatible epidemiological risk factors (immigration, travelling abroad or men who have sex with men), especially if some degree of immunosuppression concurs. These risk factors must be taken into account in any diagnostic approach to inflammatory bowel disease (IBD), and active searches for stool parasites should be performed in such cases to rule out misdiagnosis or simultaneous amoebic infection. Treatment should include intraluminal anti-amoebic treatment in order to avoid relapse and prevent further spread of the disease.
Identifiants
pubmed: 30789955
doi: 10.1371/journal.pone.0212791
pii: PONE-D-18-28744
pmc: PMC6383915
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212791Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ Case Rep. 2016 Dec 30;2016:
pubmed: 28039352
Am J Trop Med Hyg. 2005 Aug;73(2):296-300
pubmed: 16103593
Mayo Clin Proc. 2008 Oct;83(10):1154-9; quiz 1159-60
pubmed: 18828976
Parasitol Int. 2001 Sep;50(3):185-9
pubmed: 11595575
Medicine (Baltimore). 1977 Jul;56(4):325-34
pubmed: 875719
Ugeskr Laeger. 1998 Sep 14;160(38):5514-5
pubmed: 9763927
Am J Pathol. 1970 Aug;60(2):229-46
pubmed: 5457212
N Engl J Med. 2003 Apr 17;348(16):1565-73
pubmed: 12700377
Euro Surveill. 2017 Feb 2;22(5):
pubmed: 28183392
Infez Med. 2017 Sep 1;25(3):281-284
pubmed: 28956549
Lancet Infect Dis. 2012 Sep;12(9):729-36
pubmed: 22917103
Euro Surveill. 2017 Jul 27;22(30):
pubmed: 28797327
Springerplus. 2016 Sep 15;5(1):1586
pubmed: 27652159
Lancet. 2003 Mar 22;361(9362):1025-34
pubmed: 12660071
J Clin Microbiol. 1998 Feb;36(2):449-52
pubmed: 9466756
Clin Microbiol Rev. 2004 Jan;17(1):208-17
pubmed: 14726461
PLoS Negl Trop Dis. 2016 Jul 28;10(7):e0004879
pubmed: 27467600
Curr Gastroenterol Rep. 2007 Oct;9(5):429-33
pubmed: 17991346
Annu Rev Microbiol. 2002;56:39-64
pubmed: 12142490
Emerg Infect Dis. 2008 Jul;14(7):1141-3
pubmed: 18598643
Medicine (Baltimore). 1977 Jul;56(4):315-23
pubmed: 195178
New Microbes New Infect. 2017 May 15;18:50-53
pubmed: 28626584
PLoS Negl Trop Dis. 2008 Feb 27;2(2):e175
pubmed: 18301730
Eurasian J Med. 2016 Jun;48(2):124-9
pubmed: 27551176